Table 5.
LU | LU-P | HISCL | UD | Abbott | Elecsys | ESPLINE | INNO-LIA | |
---|---|---|---|---|---|---|---|---|
SERO (≥4× positive) | 94.6% | 95.7% | 72.8% | 95.7% | 94.5% | 96.7% | 97.8% | 79.3% |
SERO (≥16× positive) | 81.5% | 82.6% | 84.8% | 82.6% | 83.5% | 88.0% | 87.0% | 90.2% |
LU | LU-P | HISCL | UD | Abbott | Elecsys | ESPLINE | INNO-LIA | |
---|---|---|---|---|---|---|---|---|
SERO (≥4× positive) | 94.6% | 95.7% | 72.8% | 95.7% | 94.5% | 96.7% | 97.8% | 79.3% |
SERO (≥16× positive) | 81.5% | 82.6% | 84.8% | 82.6% | 83.5% | 88.0% | 87.0% | 90.2% |